

# CITATION REPORT

List of articles citing

**Opportunities to optimize tacrolimus therapy in solid organ transplantation: report of the European consensus conference**

**DOI: 10.1097/ftd.ob013e318198d092**

**Therapeutic Drug Monitoring, 2009, 31, 139-52.**

**Source:** <https://exaly.com/paper-pdf/47158624/citation-report.pdf>

**Version:** 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
378	Pharmacokinetics for once- versus twice-daily tacrolimus formulations in de novo kidney transplantation: a randomized, open-label trial. <b>2009</b> , 9, 2505-13		106
377	Determination of atorvastatin and its metabolite ortho-hydroxyatorvastatin in human plasma by on-line anion-exchange solid-phase extraction and liquid chromatography tandem mass spectrometry. <b>2009</b> , 394, 1687-96		21
376	Population pharmacokinetics and pharmacogenetics of tacrolimus in de novo pediatric kidney transplant recipients. <i>Clinical Pharmacology and Therapeutics</i> , <b>2009</b> , 86, 609-18	6.1	130
375	Analytical performance characteristics of the Abbott Architect i2000 Tacrolimus assay; comparisons with liquid chromatography-tandem mass spectrometry (LC-MS/MS) and Abbott IMx methods. <b>2009</b> , 410, 25-30		24
374	Multi-site analytical evaluation of the Abbott ARCHITECT tacrolimus assay. <i>Therapeutic Drug Monitoring</i> , <b>2009</b> , 31, 198-204	3.2	74
373	Time of drug administration, CYP3A5 and ABCB1 genotypes, and analytical method influence tacrolimus pharmacokinetics: a population pharmacokinetic study. <i>Therapeutic Drug Monitoring</i> , <b>2009</b> , 31, 734-42	3.2	24
372	PREDICTIVE PERFORMANCES OF DIFFERENT THERAPEUTIC DRUG MONITORING APPROACHES TO ASSESS TACROLIMUS AND MYCOPHENOLIC ACID EXPOSURE. <b>2010</b> , 65, 31-37		
371	Tacrolimus dose requirements and CYP3A5 genotype and the development of calcineurin inhibitor-associated nephrotoxicity in renal allograft recipients. <i>Therapeutic Drug Monitoring</i> , <b>2010</b> , 32, 394-404	3.2	86
370	A systematic review of the effect of CYP3A5 genotype on the apparent oral clearance of tacrolimus in renal transplant recipients. <i>Therapeutic Drug Monitoring</i> , <b>2010</b> , 32, 708-14	3.2	54
369	Interaction between everolimus and tacrolimus in renal transplant recipients: a pharmacokinetic controlled trial. <i>Transplantation</i> , <b>2010</b> , 89, 994-1000	1.8	34
368	Reduced C0 concentrations and increased dose requirements in renal allograft recipients converted to the novel once-daily tacrolimus formulation. <i>Transplantation</i> , <b>2010</b> , 90, 523-9	1.8	68
367	Polymorphisms in type I and II inosine monophosphate dehydrogenase genes and association with clinical outcome in patients on mycophenolate mofetil. <i>Pharmacogenetics and Genomics</i> , <b>2010</b> , 20, 537-43 <sup>1.9</sup>		42
366	Developmental pharmacogenetics of immunosuppressants in pediatric organ transplantation. <i>Therapeutic Drug Monitoring</i> , <b>2010</b> , 32, 688-99	3.2	30
365	A prospective, open-label, observational clinical cohort study of the association between delayed renal allograft function, tacrolimus exposure, and CYP3A5 genotype in adult recipients. <b>2010</b> , 32, 2012-23		32
364	Evaluation of the Architect tacrolimus assay in kidney, liver, and heart transplant recipients. <b>2010</b> , 53, 997-1002		34
363	Optimization of initial tacrolimus dose using pharmacogenetic testing. <i>Clinical Pharmacology and Therapeutics</i> , <b>2010</b> , 87, 721-6	6.1	231
362	Response to Pharmacogenetic vs. Concentration-Controlled Optimization of Tacrolimus Dosing in Renal Allograft Recipients <i>Clinical Pharmacology and Therapeutics</i> , <b>2010</b> , 88, 597-597	6.1	1

361	Dosing tacrolimus based on CYP3A5 genotype: will it improve clinical outcome?. <i>Clinical Pharmacology and Therapeutics</i> , <b>2010</b> , 87, 640-1	6.1	30
360	Extended release tacrolimus and antiretroviral therapy in a renal transplant recipient: so extended!. <i>Transplant International</i> , <b>2010</b> , 23, 1065-7	3	6
359	Immunsuppressiva-Medikamentenspiegelmessung [Keine Routine? / Immunosuppressant drug monitoring: a routine undertaking?. <b>2010</b> , 34, 117-128		0
358	Immunosuppressant drug monitoring [Keine Routine? / Immunosuppressant drug monitoring: a routine undertaking?]. <b>2010</b> , 34, -		
357	State of the art in therapeutic drug monitoring. <b>2010</b> , 48, 437-46		11
356	Congress of Clinical Chemistry and Laboratory Medicine 7th Annual Conference of the German Society for Clinical Chemistry and Laboratory Medicine (DGKL) Mannheim, Germany, 29th September [2nd October, 2010. <b>2010</b> , 48,		
355	Counterpoint: Is pharmacokinetic or pharmacodynamic monitoring of calcineurin inhibition therapy necessary?. <b>2010</b> , 56, 736-9		9
354	Using genetic and clinical factors to predict tacrolimus dose in renal transplant recipients. <b>2010</b> , 11, 1389-402		34
353	Novel strategies for immune monitoring in kidney transplant recipients. <b>2010</b> , 17, e63-77		5
352	Population pharmacokinetics and Bayesian estimation of tacrolimus exposure in renal transplant recipients on a new once-daily formulation. <b>2010</b> , 49, 683-92		71
351	Association of immunosuppressant-induced protein changes in the rat kidney with changes in urine metabolite patterns: a proteo-metabonomic study. <b>2010</b> , 9, 865-75		40
350	Open-well stability of reagent cartridge for affinity column-mediated immunoassay of blood tacrolimus concentration. <b>2010</b> , 411, 888-9		1
349	LC-MS/MS for immunosuppressant therapeutic drug monitoring. <b>2010</b> , 2, 1141-53		17
348	Tacrolimus-associated posterior reversible encephalopathy syndrome after solid organ transplantation. <b>2010</b> , 64, 169-77		97
347	The influence of pharmacogenetics and cofactors on clinical outcomes in kidney transplantation. <b>2011</b> , 7, 731-43		28
346	Influence of cytochrome P450 3A5 (CYP3A5) genetic polymorphism on the pharmacokinetics of the prolonged-release, once-daily formulation of tacrolimus in stable renal transplant recipients. <b>2011</b> , 50, 451-9		34
345	Once- versus twice-daily tacrolimus: are the formulations truly equivalent?. <b>2011</b> , 71, 1561-77		78
344	Immunosuppressants Pharmacogenomics. <b>2011</b> , 249-265		

343	Falsely elevated tacrolimus concentrations measured using the ACMIA method due to circulating endogenous antibodies in a kidney transplant recipient. <b>2011</b> , 412, 245-8		25
342	Pathophysiological idiosyncrasies and pharmacokinetic realities may interfere with tacrolimus dose titration in liver transplantation. <i>European Journal of Clinical Pharmacology</i> , <b>2011</b> , 67, 671-9	2.8	3
341	BK Virus in Kidney Transplant Recipients: The Influence of Immunosuppression. <b>2011</b> , 2011, 750836		20
340	Development and evaluation of a simulation procedure to take into account various assays for the Bayesian dose adjustment of tacrolimus. <i>Therapeutic Drug Monitoring</i> , <b>2011</b> , 33, 171-7	3.2	18
339	Novel polymorphisms associated with tacrolimus trough concentrations: results from a multicenter kidney transplant consortium. <i>Transplantation</i> , <b>2011</b> , 91, 300-8	1.8	131
338	CYP3A5 genotype is not related to the inpatient variability of tacrolimus clearance. <i>Therapeutic Drug Monitoring</i> , <b>2011</b> , 33, 369-71	3.2	24
337	Limited sampling strategies for monitoring tacrolimus in pediatric liver transplant recipients. <i>Therapeutic Drug Monitoring</i> , <b>2011</b> , 33, 380-6	3.2	10
336	Four-year experience with tacrolimus once-daily prolonged release in patients from phase II conversion and de novo kidney, liver, and heart studies. <i>Clinical Transplantation</i> , <b>2011</b> , 25, E1-12	3.8	51
335	Evaluation of limited sampling methods for estimation of tacrolimus exposure in adult kidney transplant recipients. <i>British Journal of Clinical Pharmacology</i> , <b>2011</b> , 71, 207-23	3.8	33
334	Population pharmacokinetic model and Bayesian estimator for two tacrolimus formulations--twice daily Prograf and once daily Advagraf. <i>British Journal of Clinical Pharmacology</i> , <b>2011</b> , 71, 391-402	3.8	79
333	Dosing equation for tacrolimus using genetic variants and clinical factors. <i>British Journal of Clinical Pharmacology</i> , <b>2011</b> , 72, 948-57	3.8	114
332	ABCB1 single-nucleotide polymorphisms determine tacrolimus response in patients with ulcerative colitis. <i>Clinical Pharmacology and Therapeutics</i> , <b>2011</b> , 89, 422-8	6.1	39
331	Bioequivalence of two tacrolimus formulations under fasting conditions in healthy male subjects. <b>2011</b> , 33, 1105-19		7
330	Tacrolimus dosing in Chinese renal transplant recipients: a population-based pharmacogenetics study. <i>European Journal of Clinical Pharmacology</i> , <b>2011</b> , 67, 787-95	2.8	30
329	Evaluation of limited sampling strategies for total and free prednisolone in adult kidney transplant recipients. <i>European Journal of Clinical Pharmacology</i> , <b>2011</b> , 67, 1243-52	2.8	14
328	Prediction tacrolimus blood levels based on the Bayesian method in adult kidney transplant patients. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , <b>2011</b> , 36, 25-33	2.7	7
327	Pharmacokinetics for once-daily versus twice-daily tacrolimus formulations in de novo liver transplantation: a randomized, open-label trial. <b>2011</b> , 17, 167-77		47
326	Mass spectrometry in laboratory medicine: When "high-tech" meets routine needs. <b>2011</b> , 44, 2-3		4

325	Suitability of chemiluminescent enzyme immunoassay for the measurement of blood tacrolimus concentrations in rheumatoid arthritis. <b>2011</b> , 44, 397-402		10
324	Impact of ATP-binding cassette, subfamily B, member 1 pharmacogenetics on tacrolimus-associated nephrotoxicity and dosage requirements in paediatric patients with liver transplant. <b>2011</b> , 10, 9-22		11
323	In vitro investigation of human UDP-glucuronosyltransferase isoforms responsible for tacrolimus glucuronidation: predominant contribution of UGT1A4. <b>2011</b> , 39, 1127-30		23
322	The need for standardization of tacrolimus assays. <b>2011</b> , 57, 1739-47		48
321	Limited sampling strategy for estimating individual exposure of tacrolimus in pediatric kidney transplant patients. <i>Therapeutic Drug Monitoring</i> , <b>2011</b> , 33, 681-7	3.2	20
320	Oseltamivir, an influenza neuraminidase inhibitor drug, does not affect the steady-state pharmacokinetic characteristics of cyclosporine, mycophenolate, or tacrolimus in adult renal transplant patients. <i>Therapeutic Drug Monitoring</i> , <b>2011</b> , 33, 699-704	3.2	11
319	Pharmacokinetics of tacrolimus converted from twice-daily formulation to once-daily formulation in Chinese stable liver transplant recipients. <b>2011</b> , 32, 1419-23		5
318	Efficacy and safety of tacrolimus for induction therapy in patients with active lupus nephritis. <i>Modern Rheumatology</i> , <b>2011</b> , 21, 282-289	3.3	20
317	Pharmacogenetic determinant of the drug interaction between tacrolimus and omeprazole. <i>Therapeutic Drug Monitoring</i> , <b>2012</b> , 34, 739-41	3.2	7
316	Pharmacokinetics in stable kidney transplant recipients after conversion from twice-daily to once-daily tacrolimus formulations. <i>Therapeutic Drug Monitoring</i> , <b>2012</b> , 34, 46-52	3.2	42
315	Tacrolimus pharmacokinetics of once- versus twice-daily formulations in de novo kidney transplantation: a substudy of a randomized phase III trial. <i>Therapeutic Drug Monitoring</i> , <b>2012</b> , 34, 143-7	3.2	23
314	The impact of sulfonylureas on tacrolimus apparent clearance revealed by a population pharmacokinetics analysis in Chinese adult liver-transplant patients. <i>Therapeutic Drug Monitoring</i> , <b>2012</b> , 34, 126-33	3.2	20
313	Immunosuppressive Drug Monitoring: Limitations of Immunoassays and the Application of Liquid Chromatography Mass Spectrometry. <b>2012</b> , 323-348		2
312	Efficacy of topical calcineurin inhibitors in lichen planus. <b>2012</b> , 16, 221-9		21
311	Therapeutic monitoring of immunotherapies in autoimmune diseases. <b>2012</b> , 18, 4550-5		3
310	Risk of tacrolimus toxicity in CYP3A5 nonexpressors treated with intravenous nicardipine after kidney transplantation. <i>Transplantation</i> , <b>2012</b> , 93, 806-12	1.8	26
309	The use of a DNA biobank linked to electronic medical records to characterize pharmacogenomic predictors of tacrolimus dose requirement in kidney transplant recipients. <i>Pharmacogenetics and Genomics</i> , <b>2012</b> , 22, 32-42	1.9	76
308	Kidney transplant outcomes are related to tacrolimus, mycophenolic acid and prednisolone exposure in the first week. <i>Transplant International</i> , <b>2012</b> , 25, 1182-93	3	28

307	Current Practice of Therapeutic Drug Monitoring: Dose Adjustment of Drugs using Pharmacokinetic Models. <b>2012</b> , 103-119		3
306	Optimizing immunosuppressive drug dosing in pediatric renal transplantation. Part of a special series on Paediatric Pharmacology, guest edited by Gianvincenzo Zuccotti, Emilio Clementi, and Massimo Molteni. <b>2012</b> , 65, 163-7		10
305	Impact of CYP3A5 genetic polymorphism on cross-reactivity in tacrolimus chemiluminescent immunoassay in kidney transplant recipients. <b>2012</b> , 414, 120-4		6
304	The neuroregenerative mechanism mediated by the Hsp90-binding immunophilin FKBP52 resembles the early steps of neuronal differentiation. <b>2012</b> , 166, 637-49		32
303	Validation of tacrolimus equation to predict troughs using genetic and clinical factors. <b>2012</b> , 13, 1141-7		28
302	In vivo CYP3A4 activity, CYP3A5 genotype, and hematocrit predict tacrolimus dose requirements and clearance in renal transplant patients. <i>Clinical Pharmacology and Therapeutics</i> , <b>2012</b> , 92, 366-75	6.1	83
301	Optimization of the use of Calcineurin inhibitors in liver transplantation. <b>2012</b> , 26, 85-95		20
300	Calcineurin inhibitors and NFAT-regulated gene expression. <b>2012</b> , 413, 1379-86		37
299	Development and validation of a sensitive LC-MS/MS method for determination of tacrolimus on dried blood spots. <b>2013</b> , 27, 327-34		23
298	Population pharmacokinetic modelling and design of a Bayesian estimator for therapeutic drug monitoring of tacrolimus in lung transplantation. <b>2012</b> , 51, 175-86		49
297	Pediatric renal transplantation in the Jordanian population: the clinical outcome measures during long-term follow-up period. <b>2012</b> , 53, 24-33		8
296	Pharmacogenetics in solid organ transplantation: a transition from kinetics to dynamics. <b>2012</b> , 13, 1679-83		
295	Tacrolimus. <b>2012</b> , 224-240		0
294	Significant interaction of tacrolimus with ritonavir during allogeneic hematopoietic SCT in an HIV-infected patient. <b>2012</b> , 47, 1140-2		8
293	A limited sampling strategy for the simultaneous estimation of tacrolimus, mycophenolic acid and unbound prednisolone exposure in adult kidney transplant recipients. <b>2012</b> , 17, 294-9		13
292	Validation of an LC-MS/MS method to determine five immunosuppressants with deuterated internal standards including MPA. <b>2012</b> , 12, 2		46
291	Tacrolimus pharmacokinetics in the early post-liver transplantation period and clinical applicability via Bayesian prediction. <i>European Journal of Clinical Pharmacology</i> , <b>2013</b> , 69, 65-74	2.8	24
290	Pharmacokinetic interaction between tacrolimus and berberine in a child with idiopathic nephrotic syndrome. <i>European Journal of Clinical Pharmacology</i> , <b>2013</b> , 69, 1861-2	2.8	12

289	Population pharmacokinetic analysis of tacrolimus in the first year after pediatric liver transplantation. <i>European Journal of Clinical Pharmacology</i> , <b>2013</b> , 69, 1533-42	2.8	25
288	Effects of traditional chinese medicine Wuzhi capsule on pharmacokinetics of tacrolimus in rats. <b>2013</b> , 41, 1398-403		40
287	Hepatotoxicity and drug interactions in liver transplant candidates and recipients. <b>2013</b> , 17, 737-47, x-xi		7
286	Standardization of LC-MS for therapeutic drug monitoring of tacrolimus. <b>2013</b> , 59, 1630-7		35
285	Tacrolimus predose concentrations do not predict the risk of acute rejection after renal transplantation: a pooled analysis from three randomized-controlled clinical trials (II) <b>2013</b> , 13, 1253-61		90
284	Caractéristiques immuno-analytiques du dosage sanguin du tacrolimus. <b>2013</b> , 28, 144-147		
283	Monitoring of tacrolimus concentrations in peripheral blood mononuclear cells: application to cardiac transplant recipients. <b>2013</b> , 46, 1538-41		41
282	Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. <b>2013</b> , 138, 103-41		2110
281	CYP3A4*22: promising newly identified CYP3A4 variant allele for personalizing pharmacotherapy. <b>2013</b> , 14, 47-62		142
280	Tacrolimus therapeutic drug monitoring in Tunisian renal transplant recipients: effect of post-transplantation period. <b>2013</b> , 28, 198-202		6
279	Opportunity to monitor immunosuppressive drugs in peripheral blood mononuclear cells: where are we and where are we going?. <b>2013</b> , 74, 109-12		17
278	Conversion from twice-daily tacrolimus capsules to once-daily extended-release tacrolimus (LCPT): a phase 2 trial of stable renal transplant recipients. <i>Transplantation</i> , <b>2013</b> , 96, 191-7	1.8	68
277	Equivalence and interchangeability of narrow therapeutic index drugs in organ transplantation. <b>2013</b> , 20, 302-307		29
276	Donor-recipient genetic diversity: the role of pharmacogenomics in kidney transplantation. <b>2013</b> , 14, 1369-72		3
275	Comparison between ultra-performance liquid chromatography with tandem mass spectrometry and a chemiluminescence immunoassay in the determination of cyclosporin A and tacrolimus levels in whole blood. <b>2013</b> , 6, 1535-1539		18
274	Prolonged influenza virus shedding and emergence of antiviral resistance in immunocompromised patients and ferrets. <b>2013</b> , 9, e1003343		77
273	Impact of CYP3A4*22 allele on tacrolimus pharmacokinetics in early period after renal transplantation: toward updated genotype-based dosage guidelines. <i>Therapeutic Drug Monitoring</i> , <b>2013</b> , 35, 608-16	3.2	58
272	Lessons from routine dose adjustment of tacrolimus in renal transplant patients based on global exposure. <i>Therapeutic Drug Monitoring</i> , <b>2013</b> , 35, 322-7	3.2	40

271	A limited sampling strategy to estimate the area under the concentration-time curve of tacrolimus modified-release once-daily preparation in renal transplant recipients. <i>Therapeutic Drug Monitoring</i> , <b>2013</b> , 35, 228-32	3.2	13
270	PharmGKB summary: cyclosporine and tacrolimus pathways. <i>Pharmacogenetics and Genomics</i> , <b>2013</b> , 23, 563-85	1.9	137
269	Low plasma concentrations of albumin influence the affinity column-mediated immunoassay method for the measurement of tacrolimus in blood during the early period after liver transplantation. <i>Therapeutic Drug Monitoring</i> , <b>2013</b> , 35, 96-100	3.2	11
268	Development and validation of limited sampling strategies for the estimation of mycophenolic acid area under the curve in adult kidney and liver transplant recipients receiving concomitant enteric-coated mycophenolate sodium and tacrolimus. <i>Therapeutic Drug Monitoring</i> , <b>2013</b> , 35, 760-9	3.2	13
267	A differential impact of mycophenolic acid, prednisolone, and tacrolimus exposure on sCD30 levels in adult kidney transplant recipients. <i>Therapeutic Drug Monitoring</i> , <b>2013</b> , 35, 240-5	3.2	3
266	Manic-like psychosis associated with elevated trough tacrolimus blood concentrations 17 years after kidney transplant. <b>2013</b> , 2013, 926395		10
265	A randomized, crossover pharmacokinetic study comparing generic tacrolimus vs. the reference formulation in subpopulations of kidney transplant patients. <i>Clinical Transplantation</i> , <b>2013</b> , 27, E685-93	3.8	13
264	Statistical tools for dose individualization of mycophenolic acid and tacrolimus co-administered during the first month after renal transplantation. <i>British Journal of Clinical Pharmacology</i> , <b>2013</b> , 75, 1277-88	3.8	19
263	Comparison of antibody-conjugated magnetic immunoassay and liquid chromatography-tandem mass spectrometry for the measurement of cyclosporine and tacrolimus in whole blood. <b>2013</b> , 26, 419-26		18
262	CYP3A5 and CYP3A4, but not ABCB1 polymorphisms affect tacrolimus dose-adjusted trough concentrations in kidney transplant recipients. <b>2014</b> , 15, 179-88		45
261	Conversion from twice daily tacrolimus capsules to once daily extended-release tacrolimus (LCP-Tacro): phase 2 trial of stable liver transplant recipients. <b>2014</b> , 20, 564-75		39
260	Transplant patient classification and tacrolimus assays: more evidence of the need for assay standardization. <i>Therapeutic Drug Monitoring</i> , <b>2014</b> , 36, 706-9	3.2	17
259	Combined effects of CYP3A5*1, POR*28, and CYP3A4*22 single nucleotide polymorphisms on early concentration-controlled tacrolimus exposure in de-novo renal recipients. <i>Pharmacogenetics and Genomics</i> , <b>2014</b> , 24, 597-606	1.9	33
258	Use of graft-derived cell-free DNA as an organ integrity biomarker to reexamine effective tacrolimus trough concentrations after liver transplantation. <i>Therapeutic Drug Monitoring</i> , <b>2014</b> , 36, 136-40	3.2	39
257	Population pharmacokinetics of tacrolimus in adult kidney transplant patients: impact of CYP3A5 genotype on starting dose. <i>Therapeutic Drug Monitoring</i> , <b>2014</b> , 36, 62-70	3.2	56
256	Role of pharmacogenomics in dialysis and transplantation. <b>2014</b> , 23, 570-7		10
255	Influence of donor-recipient CYP3A4/5 genotypes, age and fluconazole on tacrolimus pharmacokinetics in pediatric liver transplantation: a population approach. <b>2014</b> , 15, 1207-21		23
254	Population pharmacokinetic analysis of tacrolimus early after pediatric liver transplantation. <i>Therapeutic Drug Monitoring</i> , <b>2014</b> , 36, 54-61	3.2	22



253	Importance of hematocrit for a tacrolimus target concentration strategy. <i>European Journal of Clinical Pharmacology</i> , <b>2014</b> , 70, 65-77	2.8	72
252	The influence of comedication on tacrolimus blood concentration in patients subjected to kidney transplantation: a retrospective study. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , <b>2014</b> , 39, 243-53	2.7	7
251	Determination of the most influential sources of variability in tacrolimus trough blood concentrations in adult liver transplant recipients: a bottom-up approach. <b>2014</b> , 16, 379-91		29
250	Multi-center analytical evaluation of a novel automated tacrolimus immunoassay. <b>2014</b> , 47, 1069-77		26
249	The role of pharmacogenetics in the disposition of and response to tacrolimus in solid organ transplantation. <b>2014</b> , 53, 123-39		150
248	Limited sampling strategies for tacrolimus exposure (AUC <sub>0-24</sub> ) prediction after Prograf(®) and Advagraf(®) administration in children and adolescents with liver or kidney transplants. <i>Transplant International</i> , <b>2014</b> , 27, 939-48	3	9
247	Population pharmacokinetics and Bayesian estimation of tacrolimus exposure in paediatric liver transplant recipients. <i>British Journal of Clinical Pharmacology</i> , <b>2014</b> , 77, 1051-63	3.8	16
246	Extended-release tacrolimus: a review of its use in de novo kidney transplantation. <b>2014</b> , 74, 2053-64		11
245	Improved prediction of tacrolimus concentrations early after kidney transplantation using theory-based pharmacokinetic modelling. <i>British Journal of Clinical Pharmacology</i> , <b>2014</b> , 78, 509-23	3.8	58
244	Exposure to mycophenolic acid better predicts immunosuppressive efficacy than exposure to calcineurin inhibitors in renal transplant patients. <i>Clinical Pharmacology and Therapeutics</i> , <b>2014</b> , 96, 508-15	6.1	28
243	Dosage individualization in children: integration of pharmacometrics in clinical practice. <b>2014</b> , 10, 197-203		13
242	Pharmacogenetics and immunosuppressive drugs in solid organ transplantation. <b>2014</b> , 10, 725-31		62
241	Influence of TLR4 rs1927907 locus polymorphisms on tacrolimus pharmacokinetics in the early stage after liver transplantation. <i>European Journal of Clinical Pharmacology</i> , <b>2014</b> , 70, 925-31	2.8	14
240	Focus on mTOR inhibitors and tacrolimus in renal transplantation: pharmacokinetics, exposure-response relationships, and clinical outcomes. <b>2014</b> , 31, 22-32		63
239	Clinical evaluation of the QMS® Tacrolimus immunoassay. <b>2014</b> , 431, 270-5		11
238	Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP3A5 Genotype and Tacrolimus Dosing. <i>Clinical Pharmacology and Therapeutics</i> , <b>2015</b> , 98, 19-24	6.1	321
237	Improved Tacrolimus Target Concentration Achievement Using Computerized Dosing in Renal Transplant Recipients--A Prospective, Randomized Study. <i>Transplantation</i> , <b>2015</b> , 99, 2158-66	1.8	60
236	The Monitoring of Immunosuppressive Therapy with Tacrolimus in Patients with Kidney Transplant, Based on the Pharmacokinetic Criteria. <b>2015</b> , 61, 265-268		

235	Clinical laboratory diagnostics of immunosuppressants: One laboratory journey. <b>2015</b> , 24, 219-224		1
234	Impact of Laboratory Practices on Interlaboratory Variability in Therapeutic Drug Monitoring of Immunosuppressive Drugs. <i>Therapeutic Drug Monitoring</i> , <b>2015</b> , 37, 718-24	3.2	35
233	Impact of sampling time deviations on the prediction of the area under the curve using regression limited sampling strategies. <b>2015</b> , 36, 417-28		2
232	Development of Limited Sampling Strategies for the Estimation of Tacrolimus Area Under the Curve in Adult Kidney Transplant Recipients According to the Posttransplantation Time. <i>Therapeutic Drug Monitoring</i> , <b>2015</b> , 37, 524-30	3.2	2
231	African-American race modifies the influence of tacrolimus concentrations on acute rejection and toxicity in kidney transplant recipients. <i>Pharmacotherapy</i> , <b>2015</b> , 35, 569-77	5.8	34
230	[Some thoughts on the links between LC-MS/MS and therapeutic drug monitoring]. <b>2015</b> , 73, 49-53		2
229	Tacrolimus in preventing transplant rejection in Chinese patients--optimizing use. <b>2015</b> , 9, 473-85		18
228	Limited sampling strategy for prolonged-release tacrolimus in renal transplant patients by use of the dried blood spot technique. <i>European Journal of Clinical Pharmacology</i> , <b>2015</b> , 71, 811-6	2.8	16
227	Influence of combined CYP3A4 and CYP3A5 single-nucleotide polymorphisms on tacrolimus exposure in kidney transplant recipients: a study according to the post-transplant phase. <b>2015</b> , 16, 2045-54		18
226	Rapid measurement of tacrolimus in whole blood by paper spray-tandem mass spectrometry (PS-MS/MS). <b>2015</b> , 441, 99-104		65
225	Intra-patient variability in tacrolimus exposure: causes, consequences for clinical management. <i>Transplantation Reviews</i> , <b>2015</b> , 29, 78-84	3.3	111
224	Tacrolimus prolonged release (Envarsus <sup>®</sup> ): a review of its use in kidney and liver transplant recipients. <b>2015</b> , 75, 309-20		23
223	Pharmacokinetics and pharmacodynamics of tacrolimus in liver transplant recipients: inside the white blood cells. <b>2015</b> , 48, 406-11		27
222	Study of the pattern of lower respiratory tract infection within the first year in renal transplant patients. <b>2015</b> , 64, 749-753		1
221	Capability of utilizing CYP3A5 polymorphisms to predict therapeutic dosage of tacrolimus at early stage post-renal transplantation. <b>2015</b> , 16, 1840-54		7
220	Release mechanisms of tacrolimus-loaded PLGA and PLA microspheres and immunosuppressive effects of the microspheres in a rat heart transplantation model. <b>2015</b> , 492, 20-7		21
219	Efficacy of Topical Calcineurin Inhibitors in Oral Lichen Planus. <b>2015</b> , 19, 539-45		9
218	Advances in pharmacotherapy to treat kidney transplant rejection. <b>2015</b> , 16, 1627-48		8

217	Alternative matrices for therapeutic drug monitoring of immunosuppressive agents using LC-MS/MS. <b>2015</b> , 7, 1037-58		25
216	Clinical Pharmacokinetics of Once-Daily Tacrolimus in Solid-Organ Transplant Patients. <b>2015</b> , 54, 993-1025		64
215	The need for minimization strategies: current problems of immunosuppression. <i>Transplant International</i> , <b>2015</b> , 28, 891-900	3	79
214	Dose increase needed in most cystic fibrosis lung transplantation patients when changing from twice- to once-daily tacrolimus oral administration. <i>European Journal of Clinical Pharmacology</i> , <b>2015</b> , 71, 715-722	2.8	6
213	Effects of CYP3A5 genotypes, ABCB1 C3435T and G2677T/A polymorphism on pharmacokinetics of Tacrolimus in Chinese adult liver transplant patients. <i>Xenobiotica</i> , <b>2015</b> , 45, 840-6	2	31
212	Multicenter evaluation of the thermo scientific prelude for measurement of immunosuppressant drugs using sample preparation liquid chromatography-tandem mass spectrometry. <i>Therapeutic Drug Monitoring</i> , <b>2015</b> , 37, 161-71	3.2	12
211	Development of a population PK model of tacrolimus for adaptive dosage control in stable kidney transplant patients. <i>Therapeutic Drug Monitoring</i> , <b>2015</b> , 37, 246-55	3.2	26
210	Use of generic tacrolimus in elderly renal transplant recipients: precaution is needed. <i>Transplantation</i> , <b>2015</b> , 99, 528-32	1.8	33
209	How to handle missed or delayed doses of tacrolimus in renal transplant recipients? A pharmacokinetic investigation. <b>2015</b> , 100, 281-7		12
208	Association between interleukin-18 promoter variants and tacrolimus pharmacokinetics in Chinese renal transplant patients. <i>European Journal of Clinical Pharmacology</i> , <b>2015</b> , 71, 191-8	2.8	6
207	Therapeutic drug monitoring in pediatric renal transplantation. <b>2015</b> , 30, 253-65		15
206	Falsely Elevated Tacrolimus Concentrations Using Chemiluminescence Microparticle Immunoassay in Kidney Transplant Patient. <b>2016</b> , 30, 138		
205	Monitoring free mycophenolic acid concentration: Is there any clinical advantage?. <b>2016</b> , 83-107		3
204	Effect of Breakfast on the Exposure of the Once-Daily Tacrolimus Formulation in Stable Kidney Transplant Recipients. <i>Therapeutic Drug Monitoring</i> , <b>2016</b> , 38, 456-62	3.2	7
203	Pretransplant Tacrolimus Dose Requirements Predict Early Posttransplant Dose Requirements in Blood Group ABO-Incompatible Kidney Transplant Recipients. <i>Therapeutic Drug Monitoring</i> , <b>2016</b> , 38, 217-22	3.2	2
202	Population pharmacokinetics of tacrolimus in Thai kidney transplant patients: comparison with similar data from other populations. <i>Journal of Clinical Pharmacy and Therapeutics</i> , <b>2016</b> , 41, 310-28	2.2	24
201	Long-Term Clinical Impact of Adaptation of Initial Tacrolimus Dosing to CYP3A5 Genotype. <b>2016</b> , 16, 2670-5		36
200	External evaluation of published population pharmacokinetic models of tacrolimus in adult renal transplant recipients. <i>British Journal of Clinical Pharmacology</i> , <b>2016</b> , 81, 891-907	3.8	44

199	Low-target tacrolimus in de novo standard risk renal transplant recipients: A single-centre experience. <b>2016</b> , 21, 821-7		5
198	Evaluation of the New Siemens Tacrolimus Assay on the Dimension EXL Integrated Chemistry System Analyzer: Comparison With an Ultra-Performance Liquid Chromatography-Tandem Mass Spectrometry Method. <i>Therapeutic Drug Monitoring</i> , <b>2016</b> , 38, 808-812	3.2	11
197	Therapeutic Drug Monitoring of Everolimus: A Consensus Report. <i>Therapeutic Drug Monitoring</i> , <b>2016</b> , 38, 143-69	3.2	71
196	Population Pharmacokinetic Modelling and Bayesian Estimation of Tacrolimus Exposure: Is this Clinically Useful for Dosage Prediction Yet?. <b>2016</b> , 55, 1295-1335		51
195	The Effect of Weight and CYP3A5 Genotype on the Population Pharmacokinetics of Tacrolimus in Stable Paediatric Renal Transplant Recipients. <b>2016</b> , 55, 1129-43		24
194	Assuring the Proper Analytical Performance of Measurement Procedures for Immunosuppressive Drug Concentrations in Clinical Practice: Recommendations of the International Association of Therapeutic Drug Monitoring and Clinical Toxicology Immunosuppressive Drug Scientific Committee. <i>Therapeutic Drug Monitoring</i> , <b>2016</b> , 38, 170-83	3.2	65
193	Pharmacokinetic study of once-daily formulation of tacrolimus (Advagraf) in stable Chinese kidney transplant recipients. <b>2016</b> , 19, 1-6		
192	A preliminary study searching for the right dose of tacrolimus in very young (4 years) renal transplant patients. <b>2016</b> , 68, 1366-1372		3
191	Evaluation of 2 Batched Pretreatment Systems for the Measurement of Whole Blood Tacrolimus on the ARCHITECT Immunoassay Analyzer. <b>2016</b> , 47, 268-274		2
190	Intra-cellular immunosuppressive drugs monitoring: A step forward towards better therapeutic efficacy after organ transplantation?. <b>2016</b> , 111, 610-618		36
189	Immunosuppression and Results in Renal Transplantation. <b>2016</b> , 15, 415-429		8
188	Inter-laboratory Variability of Current Immunoassay Methods for Tacrolimus among Japanese Hospitals. <b>2016</b> , 39, 1331-7		10
187	A high performance liquid chromatography tandem mass spectrometry for the quantification of tacrolimus in human bile in liver transplant recipients. <b>2016</b> , 1475, 55-63		10
186	Validation of a 2-Point Limited Sampling Strategy to Predict the Tacrolimus Area-Under-the-12-Hour-Curve in Kidney Transplant Recipients. <i>Therapeutic Drug Monitoring</i> , <b>2016</b> , 38, 614-20	3.2	3
185	Correlation of Hematocrit and Tacrolimus Level in Liver Transplant Recipients. <i>Transplantation Proceedings</i> , <b>2016</b> , 48, 1176-8	1.1	13
184	Donor ABCB1 3435 C>T genetic polymorphisms influence early renal function in kidney transplant recipients treated with tacrolimus. <b>2016</b> , 17, 249-57		12
183	Application of liquid chromatography combined with mass spectrometry or tandem mass spectrometry for therapeutic drug monitoring of immunosuppressants. <b>2016</b> , 57-81		3
182	Graft-derived cell-free DNA as a marker of graft integrity after transplantation. <b>2016</b> , 153-176		2

181	Clinical implementation of pharmacogenetics. <b>2016</b> , 31, 9-16		13
180	Pharmacokinetics, Pharmacodynamics and Pharmacogenomics of Immunosuppressants in Allogeneic Haematopoietic Cell Transplantation: Part I. <b>2016</b> , 55, 525-50		20
179	Recent advances in therapeutic drug monitoring of immunosuppressive drugs. <b>2016</b> , 79, 257-268		31
178	[Applied pharmacogenetic]. <b>2016</b> , 12 Suppl 1, S99-S103		
177	Impact of immunosuppressive drugs on the therapeutic efficacy of ex vivo expanded human regulatory T cells. <b>2016</b> , 101, 91-100		48
176	Intracellular concentrations of immunosuppressants. <b>2016</b> , 199-226		7
175	Therapeutic drug monitoring - Key to personalized pharmacotherapy. <b>2017</b> , 50, 375-379		9
174	Application of Machine-Learning Models to Predict Tacrolimus Stable Dose in Renal Transplant Recipients. <b>2017</b> , 7, 42192		60
173	Population Pharmacokinetics and Bayesian Estimators for Refined Dose Adjustment of a New Tacrolimus Formulation in Kidney and Liver Transplant Patients. <b>2017</b> , 56, 1491-1498		27
172	Simultaneous Determination of Protein-Unbound Cyclosporine A and Mycophenolic Acid in Kidney Transplant Patients Using Liquid Chromatography-Tandem Mass Spectrometry. <i>Therapeutic Drug Monitoring</i> , <b>2017</b> , 39, 211-219	3.2	12
171	Cognitive Evaluation in Liver Transplant Patients Under Calcineurin Inhibitor Maintenance Therapy. <i>Transplantation Direct</i> , <b>2017</b> , 3, e146	2.3	4
170	High Tacrolimus Clearance Is a Risk Factor for Acute Rejection in the Early Phase After Renal Transplantation. <i>Transplantation</i> , <b>2017</b> , 101, e273-e279	1.8	27
169	Improved Open-Well Stability of Affinity Column-Mediated Immunoassay Reagent for Determining Blood Tacrolimus. <i>Therapeutic Drug Monitoring</i> , <b>2017</b> , 39, 202-203	3.2	0
168	Pharmacokinetics of prolonged-release tacrolimus versus immediate-release tacrolimus in de novo liver transplantation: A randomized phase III substudy. <i>Clinical Transplantation</i> , <b>2017</b> , 31, e12958	3.8	6
167	A New CYP3A5*3 and CYP3A4*22 Cluster Influencing Tacrolimus Target Concentrations: A Population Approach. <b>2017</b> , 56, 963-975		46
166	Clinical impact of the CYP3A5 6986A>G allelic variant on kidney transplantation outcomes. <b>2017</b> , 18, 165-173		10
165	Evaluation of Experiences with Immunosuppressive Drugs in Transplantation: Validation of the MESI Scale in French. <b>2017</b> , 31, 455-465		1
164	Association Between Tacrolimus Pharmacokinetics and Cytochrome P450 3A5 and Multidrug Resistance Protein 1 Exon 21 Polymorphisms. <i>Transplantation Proceedings</i> , <b>2017</b> , 49, 1492-1498	1.1	4

163	Cocaine Detection in Maternal and Neonatal Hair: Implications to Fetal Toxicology: Erratum. <i>Therapeutic Drug Monitoring</i> , <b>2017</b> , 39, 203-203	3.2	0
162	Differential T Cell Signaling Pathway Activation by Tacrolimus and Belatacept after Kidney Transplantation: Post Hoc Analysis of a Randomised-Controlled Trial. <b>2017</b> , 7, 15135		8
161	Pharmacokinetic considerations related to therapeutic drug monitoring of tacrolimus in kidney transplant patients. <b>2017</b> , 13, 1225-1236		69
160	Pharmacodynamic Monitoring of Tacrolimus-Based Immunosuppression in CD14+ Monocytes After Kidney Transplantation. <i>Therapeutic Drug Monitoring</i> , <b>2017</b> , 39, 463-471	3.2	4
159	Predictive Modeling of Tacrolimus Dose Requirement Based on High-Throughput Genetic Screening. <b>2017</b> , 17, 1008-1019		10
158	Dynamic effects of CYP3A5 polymorphism on dose requirement and trough concentration of tacrolimus in renal transplant recipients. <i>Journal of Clinical Pharmacy and Therapeutics</i> , <b>2017</b> , 42, 93-97	2.2	9
157	Pharmacoepidemiology of tacrolimus in pediatric liver transplantation. <i>Pediatric Transplantation</i> , <b>2017</b> , 21, e12982	1.8	5
156	A Low Concentration of Tacrolimus/Semifluorinated Alkane (SFA) Eyedrop Suppresses Intraocular Inflammation in Experimental Models of Uveitis. <b>2017</b> , 17, 211-220		8
155	Individualizing Transplant Therapy. <b>2017</b> , 255-279		2
154	Evaluation of electrochemiluminescence immunoassays for immunosuppressive drugs on the Roche cobas e411 analyzer. <i>F1000Research</i> , <b>2017</b> , 6, 1832	3.6	4
153	Pharmacokinetic Therapeutic Drug Monitoring of Advagraf in More Than 500 Adult Renal Transplant Patients, Using an Expert System Online. <i>Therapeutic Drug Monitoring</i> , <b>2018</b> , 40, 285-291	3.2	15
152	A simple and highly sensitive on-line column extraction liquid chromatography-tandem mass spectrometry method for the determination of protein-unbound tacrolimus in human plasma samples. <b>2018</b> , 1547, 45-52		13
151	Highly Fluorescent Magnetic Nanobeads with a Remarkable Stokes Shift as Labels for Enhanced Detection in Immunoassays. <b>2018</b> , 14, e1703810		21
150	Survival Time to Biopsy-Proven Acute Rejection and Tacrolimus Adverse Drug Reactions in Pediatric Liver Transplantation. <i>Therapeutic Drug Monitoring</i> , <b>2018</b> , 40, 401-410	3.2	7
149	Pharmacokinetic models to assist the prescriber in choosing the best tacrolimus dose. <b>2018</b> , 130, 316-321		19
148	Current progress of tacrolimus dosing in solid organ transplant recipients: Pharmacogenetic considerations. <b>2018</b> , 102, 107-114		19
147	Recent advances in analytical methods for the therapeutic drug monitoring of immunosuppressive drugs. <b>2018</b> , 10, 81-94		50
146	Lower tacrolimus exposure and time in therapeutic range increase the risk of de novo donor-specific antibodies in the first year of kidney transplantation. <b>2018</b> , 18, 907-915		67

145	A comparison of the effects of CYP3A5 polymorphism on tacrolimus blood concentrations measured by 4 immunoassay methods in renal transplant patients. <i>Journal of Clinical Pharmacy and Therapeutics</i> , <b>2018</b> , 43, 181-188	2.2	6
144	Incidence and impact of adverse drug events contributing to hospital readmissions in kidney transplant recipients. <b>2018</b> , 163, 430-435		5
143	Performance of the Dimension TAC assay and comparison of multiple platforms for the measurement of tacrolimus. <b>2018</b> , 32, e22357		5
142	genotype-based model to predict tacrolimus dosage in the early postoperative period after living donor liver transplantation. <b>2018</b> , 14, 2119-2126		6
141	Tacrolimus Concentrations Measured in Excreted Bile in Liver Transplant Recipients: The STABLE Study. <b>2018</b> , 40, 2088-2098		3
140	Multi-center Performance Evaluations of Tacrolimus and Cyclosporine Electrochemiluminescence Immunoassays in the Asia-Pacific Region. <b>2018</b> , 38, 85-94		9
139	Impact of reduced exposure to calcineurin inhibitors on the development of de novo DSA: a cohort of non-immunized first kidney graft recipients between 2007 and 2014. <b>2018</b> , 19, 232		12
138	Comparative pharmacokinetics of tacrolimus in de novo pediatric transplant recipients randomized to receive immediate- or prolonged-release tacrolimus. <i>Pediatric Transplantation</i> , <b>2018</b> , 22, e13289	1.8	4
137	Once-daily vs twice-daily tacrolimus for de novo living kidney transplantation patients including ABO/HLA compatible and incompatible: A randomized trial. <i>Clinical Transplantation</i> , <b>2018</b> , 32, e13423	3.8	1
136	Accuracy evaluation of Roche and Siemens tacrolimus and cyclosporine assays in comparison with liquid chromatography-tandem mass spectrometry. <b>2018</b> , 78, 431-438		3
135	A randomized clinical trial of age and genotype-guided tacrolimus dosing after pediatric solid organ transplantation. <i>Pediatric Transplantation</i> , <b>2018</b> , 22, e13285	1.8	16
134	Therapeutic drug monitoring of tacrolimus and mycophenolic acid in outpatient renal transplant recipients using a volumetric dried blood spot sampling device. <i>British Journal of Clinical Pharmacology</i> , <b>2018</b> , 84, 2889-2902	3.8	39
133	Tacrolimus Population Pharmacokinetics and Multiple CYP3A5 Genotypes in Black and White Renal Transplant Recipients. <b>2018</b> , 58, 1184-1195		22
132	Analysis of NFATc1 amplification in T cells for pharmacodynamic monitoring of tacrolimus in kidney transplant recipients. <i>PLoS ONE</i> , <b>2018</b> , 13, e0201113	3.7	7
131	Tacrolimus population pharmacokinetic models according to CYP3A5/CYP3A4/POR genotypes in Chinese Han renal transplant patients. <b>2018</b> , 19, 1013-1025		10
130	Precision Medicine and Personalized Approach to Renal Transplantation. <b>2018</b> , 38, 346-354		6
129	Artificial neural network model for predicting the bioavailability of tacrolimus in patients with renal transplantation. <i>PLoS ONE</i> , <b>2018</b> , 13, e0191921	3.7	25
128	Once-daily, prolonged-release tacrolimus vs twice-daily, immediate-release tacrolimus in de novo living-donor liver transplantation: A Phase 4, randomized, open-label, comparative, single-center study. <i>Clinical Transplantation</i> , <b>2018</b> , 32, e13376	3.8	2

127	Tacrolimus intra-patient variability is not associated with chronic active antibody mediated rejection. <i>PLoS ONE</i> , <b>2018</b> , 13, e0196552	3.7	20
126	Toward a robust tool for pharmacokinetic-based personalization of treatment with tacrolimus in solid organ transplantation: A model-based meta-analysis approach. <i>British Journal of Clinical Pharmacology</i> , <b>2019</b> , 85, 2793-2823	3.8	12
125	Limited sampling strategy to predict the area under the curve of tacrolimus in Mexican renal transplant pediatric patients receiving Prograf or non-innovator formulations. <i>Pediatric Transplantation</i> , <b>2019</b> , 23, e13595	1.8	1
124	Immunomonitoring of Tacrolimus in Healthy Volunteers: The First Step from PK- to PD-Based Therapeutic Drug Monitoring?. <b>2019</b> , 20,		5
123	Identifying the active components of Baihe-Zhimu decoction that ameliorate depressive disease by an effective integrated strategy: a systemic pharmacokinetics study combined with classical depression model tests. <b>2019</b> , 14, 37		5
122	Low incidence of acute rejection within 6 months of kidney transplantation in HIV-infected recipients treated with raltegravir: the Agence Nationale de Recherche sur le Sida et les Hépatites Virales (ANRS) 153 TREVE trial. <b>2019</b> , 20, 202-213		3
121	Prediction of tacrolimus dosage in the early period after heart transplantation: a population pharmacokinetic approach. <b>2019</b> , 20, 21-35		12
120	A randomized, open-label pharmacokinetic trial of tacrolimus extended-release dosing in obese de novo kidney transplant recipients. <i>Clinical Transplantation</i> , <b>2019</b> , 33, e13640	3.8	2
119	A Novel, Dose-Adjusted Tacrolimus Trough-Concentration Model for Predicting and Estimating Variance After Kidney Transplantation. <b>2019</b> , 19, 201-212		2
118	Differences in CYP3A genotypes of a liver transplant recipient and the donor liver graft and adjustment of tacrolimus dose. <i>British Journal of Clinical Pharmacology</i> , <b>2019</b> , 85, 1852-1854	3.8	6
117	Identification of Factors Affecting Tacrolimus Trough Levels in Latin American Pediatric Liver Transplant Patients. <b>2019</b> , 25, 1397-1407		0
116	Measurement of calcineurin activity in peripheral blood mononuclear cells by ultra-high performance liquid chromatography-tandem mass spectrometry. Renal transplant recipients application (pharmacodynamic monitoring). <b>2019</b> , 495, 287-293		5
115	Pharmacokinetics and Pharmacodynamics of Once-daily Prolonged-release Tacrolimus in Liver Transplant Recipients. <b>2019</b> , 41, 882-896.e3		3
114	Population pharmacokinetic model and Bayesian estimator for 2 tacrolimus formulations in adult liver transplant patients. <i>British Journal of Clinical Pharmacology</i> , <b>2019</b> , 85, 1740-1750	3.8	11
113	Incorporation of Gene-Environment Interaction Terms Improved the Predictive Accuracy of Tacrolimus Stable Dose Algorithms in Chinese Adult Renal Transplant Recipients. <b>2019</b> , 59, 890-899		4
112	Tacrolimus exposure early after lung transplantation and exploratory associations with acute cellular rejection. <i>European Journal of Clinical Pharmacology</i> , <b>2019</b> , 75, 879-888	2.8	1
111	Population pharmacokinetics of immediate- and prolonged-release tacrolimus formulations in liver, kidney and heart transplant recipients. <i>British Journal of Clinical Pharmacology</i> , <b>2019</b> , 85, 1692-1703	3.8	12
110	Tacrolimus Therapeutic Drug Monitoring in Stable Kidney Transplantation and Individuation of CYP3A5 Genotype. <i>Transplantation Proceedings</i> , <b>2019</b> , 51, 2917-2920	1.1	4



109	Tacrolimus Can Be Reliably Measured With Volumetric Absorptive Capillary Microsampling Throughout the Dose Interval in Renal Transplant Recipients. <i>Therapeutic Drug Monitoring</i> , <b>2019</b> , 41, 607-614	3.2	19
108	Is There a Temporal Relationship Between Trough Whole Blood Tacrolimus Concentration and Acute Rejection in the First 14 Days After Kidney Transplantation?. <i>Therapeutic Drug Monitoring</i> , <b>2019</b> , 41, 528-532	3.2	4
107	Effect of tacrolimus dispositional genetics on acute rejection in the first 2 weeks and estimated glomerular filtration rate in the first 3 months following kidney transplantation. <i>Pharmacogenetics and Genomics</i> , <b>2019</b> , 29, 9-17	1.9	5
106	Therapeutic Drug Monitoring of Tacrolimus-Personalized Therapy: Second Consensus Report. <i>Therapeutic Drug Monitoring</i> , <b>2019</b> , 41, 261-307	3.2	163
105	Reduced variability in tacrolimus pharmacokinetics following intramuscular injection compared to oral administration in cynomolgus monkeys: Investigating optimal dosing regimens. <b>2019</b> , 139, 65-71		1
104	The impact of tacrolimus exposure on extrarenal adverse effects in adult renal transplant recipients. <i>British Journal of Clinical Pharmacology</i> , <b>2019</b> , 85, 516-529	3.8	14
103	Pharmacogenetics of Membrane Transporters of Tacrolimus in Solid Organ Transplantation. <b>2019</b> , 58, 593-613		20
102	The potential impact of hematocrit correction on evaluation of tacrolimus target exposure in pediatric kidney transplant patients. <b>2019</b> , 34, 507-515		7
101	Population Pharmacokinetics of Tacrolimus in Transplant Recipients: What Did We Learn About Sources of Interindividual Variabilities?. <b>2019</b> , 59, 309-325		26
100	Isotope-labeled versus analog internal standard in LC-MS/MS method for tacrolimus determination in human whole blood samples - A compensation of matrix effects. <b>2019</b> , 1104, 220-227		3
99	Clinical aspects of tacrolimus use in paediatric renal transplant recipients. <b>2019</b> , 34, 31-43		14
98	Impact of body composition on pharmacokinetics of tacrolimus in liver transplantation recipients. <i>Xenobiotica</i> , <b>2020</b> , 50, 186-191	2	3
97	Adherence profiles in kidney transplant patients: Causes and consequences. <b>2020</b> , 103, 189-198		11
96	Inpatient Variability of Tacrolimus Exposure in Solid Organ Transplantation: A Novel Marker for Clinical Outcome. <i>Clinical Pharmacology and Therapeutics</i> , <b>2020</b> , 107, 347-358	6.1	33
95	FK506 regulates Ca release evoked by inositol 1,4,5-trisphosphate independently of FK-binding protein in endothelial cells. <b>2020</b> , 177, 1131-1149		10
94	Evaluation of Concentration Errors and Inappropriate Dose Tailoring of Tacrolimus Caused by Sampling-Time Deviations in Pediatric Patients With Primary Nephrotic Syndrome. <i>Therapeutic Drug Monitoring</i> , <b>2020</b> , 42, 392-399	3.2	1
93	Validation and evaluation of four sample preparation methods for the quantification of intracellular tacrolimus in peripheral blood mononuclear cells by UHPLC-MS/MS. <b>2020</b> , 503, 210-217		1
92	Unbound Plasma, Total Plasma, and Whole-Blood Tacrolimus Pharmacokinetics Early After Thoracic Organ Transplantation. <b>2020</b> , 59, 771-780		10

91	Tacrolimus Area Under the Concentration Versus Time Curve Monitoring, Using Home-Based Volumetric Absorptive Capillary Microsampling. <i>Therapeutic Drug Monitoring</i> , <b>2020</b> , 42, 407-414	3.2	9
90	Assessing immunosuppressive drug concentrations in clinical practice. <b>2020</b> , 7, 277-290		
89	Nuclear factor of activated T cells as potential pharmacodynamic biomarker for the risk of acute and subclinical rejection in de novo liver recipients. <b>2020</b> , 40, 931-946		3
88	Redefining Therapeutic Drug Monitoring of Tacrolimus in Patients Undergoing Liver Transplantation: A Target Trough Concentration of 4-7 ng/mL During the First Month After Liver Transplantation is Safe and Improves Graft and Renal Function. <i>Therapeutic Drug Monitoring</i> , <b>2020</b> , 42, 654-670	3.2	1
87	Measuring Intracellular Concentrations of Calcineurin Inhibitors: Expert Consensus from the International Association of Therapeutic Drug Monitoring and Clinical Toxicology Expert Panel. <i>Therapeutic Drug Monitoring</i> , <b>2020</b> , 42, 665-670	3.2	6
86	Frequency of CYP3A5 Genetic Polymorphisms and Tacrolimus Pharmacokinetics in Pediatric Liver Transplantation. <i>Pharmaceutics</i> , <b>2020</b> , 12,	6.4	3
85	No Apparent Influence of Nonadherence on Tacrolimus Inpatient Variability in Stable Kidney Transplant Recipients. <i>Therapeutic Drug Monitoring</i> , <b>2020</b> , 42, 702-709	3.2	6
84	Evaluation of the impact of Tacrolimus-based immunosuppression on Heidelberg liver transplant cohort (HDTACRO): Study protocol for an investigator initiated, non-interventional prospective study. <b>2020</b> , 99, e22180		
83	Impacts of High Intra- and Inter-Individual Variability in Tacrolimus Pharmacokinetics and Fast Tacrolimus Metabolism on Outcomes of Solid Organ Transplant Recipients. <i>Journal of Clinical Medicine</i> , <b>2020</b> , 9,	5.1	3
82	Appreciating the Impact of Tacrolimus Sampling Time Deviations in Pediatric Patients With Nephrotic Syndrome. <i>Therapeutic Drug Monitoring</i> , <b>2020</b> , 42, 354-356	3.2	0
81	Association of the ward pharmacy service with active implementation of therapeutic drug monitoring for vancomycin and teicoplanin-an epidemiological surveillance study using Japanese large health insurance claims database. <b>2020</b> , 6, 18		1
80	Beyond Single Nucleotide Polymorphisms: Composite and Haplotype Associations to Tacrolimus Pharmacokinetics in Black and White Renal Transplant Recipients. <b>2020</b> , 11, 889		3
79	Pharmacokinetics in Patients with Cystic Fibrosis: A Systematic Review of Data Published Between 1999 and 2019. <b>2020</b> , 59, 1551-1573		6
78	Analyses of AUC and C Compliances within Therapeutic Ranges in Kidney Recipients Receiving Cyclosporine or Tacrolimus. <i>Journal of Clinical Medicine</i> , <b>2020</b> , 9,	5.1	1
77	Effects of CYP3A5, ABCB1 and POR*28 polymorphisms on pharmacokinetics of tacrolimus in the early period after renal transplantation. <i>Xenobiotica</i> , <b>2020</b> , 50, 1501-1509	2	5
76	Relationship Between Change Rate of Tacrolimus Clearance During Continuous Intravenous Infusion and Recipient Recovery at an Early Stage After Living Donor Liver Transplantation. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , <b>2020</b> , 45, 619-626	2.7	0
75	Transforming growth factor beta 1 levels in the blood of pediatric liver recipients: Clinical and biochemical correlations. <i>Pediatric Transplantation</i> , <b>2020</b> , 24, e13693	1.8	1
74	Failure of Achieving Tacrolimus Target Blood Concentration Might Be Avoided by a Wide Genotyping of Transplanted Patients: Evidence from a Retrospective Study. <i>Journal of Personalized Medicine</i> , <b>2020</b> , 10,	3.6	1

73	Optimization of tacrolimus in kidney transplantation: New pharmacokinetic perspectives. <i>Transplantation Reviews</i> , <b>2020</b> , 34, 100531	3.3	9
72	Systematic external evaluation of published population pharmacokinetic models for tacrolimus in adult liver transplant recipients. <i>European Journal of Pharmaceutical Sciences</i> , <b>2020</b> , 145, 105237	5.1	6
71	A limited sampling strategy to estimate exposure of once-daily modified release tacrolimus in renal transplant recipients using linear regression analysis and comparison with Bayesian population pharmacokinetics in different cohorts. <i>European Journal of Clinical Pharmacology</i> , <b>2020</b> , 76, 685-693	2.8	3
70	Relationship between 2-Hour Tacrolimus Concentrations and Clinical Outcomes in Long Term Kidney Transplantation. <i>Pharmacy (Basel, Switzerland)</i> , <b>2020</b> , 8,	2	3
69	Tablets or oral suspension for posaconazole in lung transplant recipients? Consequences for trough concentrations of tacrolimus and everolimus. <i>British Journal of Clinical Pharmacology</i> , <b>2021</b> , 87, 427-435	3.8	2
68	Topical Calcineurin Inhibitors. <b>2021</b> , 549-556.e5		0
67	Tacrolimus Measured in Capillary Volumetric Microsamples in Pediatric Patients-A Cross-Validation Study. <i>Therapeutic Drug Monitoring</i> , <b>2021</b> , 43, 371-375	3.2	3
66	An Integrated Clinical and Genetic Prediction Model for Tacrolimus Levels in Pediatric Solid Organ Transplant Recipients. <i>Transplantation</i> , <b>2021</b> ,	1.8	0
65	Microsampling Devices for Routine Therapeutic Drug Monitoring-Are We There Yet?. <i>Therapeutic Drug Monitoring</i> , <b>2021</b> , 43, 322-334	3.2	2
64	Sustained Inhibition of Calcineurin Activity With a Melt-Dose Once-daily Tacrolimus Formulation in Renal Transplant Recipients. <i>Clinical Pharmacology and Therapeutics</i> , <b>2021</b> , 110, 238-247	6.1	2
63	Tacrolimus dose, blood concentrations and acute nephrotoxicity, but not CYP3A5/ABCB1 genetics, are associated with allograft tacrolimus concentrations in renal transplant recipients. <i>British Journal of Clinical Pharmacology</i> , <b>2021</b> , 87, 3901-3909	3.8	3
62	Influence of the Circadian Timing System on Tacrolimus Pharmacokinetics and Pharmacodynamics After Kidney Transplantation. <i>Frontiers in Pharmacology</i> , <b>2021</b> , 12, 636048	5.6	3
61	Population pharmacokinetics and genetics of oral meltdose tacrolimus (Envarsus) in stable adult liver transplant recipients. <i>British Journal of Clinical Pharmacology</i> , <b>2021</b> , 87, 4262-4272	3.8	1
60	Efficacy of Tacrolimus in Uveitis, and the Usefulness of Serum Tacrolimus Levels in Predicting Disease Control. Results from a Single Large Center. <i>Ocular Immunology and Inflammation</i> , <b>2021</b> , 1-5	2.8	1
59	Tacrolimus exposure windows responsible for <i>Listeria monocytogenes</i> infection susceptibility. <i>Transplant Infectious Disease</i> , <b>2021</b> , 23, e13655	2.7	0
58	Drug-Drug Interaction between Tacrolimus and Vonoprazan in Kidney Transplant Recipients. <i>Journal of Clinical Medicine</i> , <b>2021</b> , 10,	5.1	4
57	Can We Predict Individual Concentrations of Tacrolimus After Liver Transplantation? Application and Tweaking of a Published Population Pharmacokinetic Model in Clinical Practice. <i>Therapeutic Drug Monitoring</i> , <b>2021</b> , 43, 490-498	3.2	1
56	Wuzhi Capsule Dosage Affects Tacrolimus Elimination in Adult Kidney Transplant Recipients, as Determined by a Population Pharmacokinetics Analysis. <i>Pharmacogenomics and Personalized Medicine</i> , <b>2021</b> , 14, 1093-1106	2.1	2

55	Influential Factors and Efficacy Analysis of Tacrolimus Concentration After Allogeneic Hematopoietic Stem Cell Transplantation in Children with $\beta$ -Thalassemia Major. <i>Pharmacogenomics and Personalized Medicine</i> , <b>2021</b> , 14, 1221-1237	2.1	
54	Efficacy and safety of tacrolimus for induction therapy in patients with active lupus nephritis. <i>Modern Rheumatology</i> , <b>2011</b> , 21, 282-9	3.3	11
53	Therapeutic Drugs and Their Management. <b>2012</b> , 1057-1108		2
52	Lower tacrolimus daily dose requirements and acute rejection rates in the CYP3A5 nonexpressers than expressers. <i>Pharmacogenetics and Genomics</i> , <b>2011</b> , 21, 713-20	1.9	54
51	Quantitation of Tacrolimus in Human Whole Blood Samples Using the MITRA Microsampling Device. <i>Therapeutic Drug Monitoring</i> , <b>2021</b> , 43, 364-370	3.2	3
50	Pharmacokinetic modeling and development of Bayesian estimators in kidney transplant patients receiving the tacrolimus once-daily formulation. <i>Therapeutic Drug Monitoring</i> , <b>2010</b> , 32, 129-35	3.2	39
49	Effects of Wuzhi Capsules on Blood Concentration of Tacrolimus in Renal Transplant Recipients. <i>Annals of Transplantation</i> , <b>2019</b> , 24, 594-604	1.4	7
48	Evaluation of electrochemiluminescence immunoassays for immunosuppressive drugs on the Roche cobas e411 analyzer. <i>F1000Research</i> , <b>2017</b> , 6, 1832	3.6	12
47	Impact of the CYP3A5, CYP3A4, COMT, IL-10 and POR genetic polymorphisms on tacrolimus metabolism in Chinese renal transplant recipients. <i>PLoS ONE</i> , <b>2014</b> , 9, e86206	3.7	54
46	ABCB1 1199G>A genetic polymorphism (Rs2229109) influences the intracellular accumulation of tacrolimus in HEK293 and K562 recombinant cell lines. <i>PLoS ONE</i> , <b>2014</b> , 9, e91555	3.7	33
45	Conversion ratio of tacrolimus switching from intravenous infusion to oral administration after lung transplantation. <i>Journal of Thoracic Disease</i> , <b>2020</b> , 12, 4292-4298	2.6	1
44	The Application of Machine Learning Techniques in Clinical Drug Therapy. <i>Current Computer-Aided Drug Design</i> , <b>2019</b> , 15, 111-119	1.4	7
43	Change in Mycophenolate and Tacrolimus Exposure by Transplant Vintage and Race. <i>Experimental and Clinical Transplantation</i> , <b>2019</b> , 17, 707-713	0.8	1
42	Monitoring Intra-cellular Tacrolimus Concentrations in Solid Organ Transplantation: Use of Peripheral Blood Mononuclear Cells and Graft Biopsy Tissue. <i>Frontiers in Pharmacology</i> , <b>2021</b> , 12, 733285 <sup>5.6</sup>		0
41	Pharmacogenomics of Immunosuppressants. 70-97		
40	Beaned. <b>2015</b> , 693-695		
39	. <b>2016</b> , 14,		
38	A Pilot Study of the Pharmacokinetics of the Modified-Release Once-Daily Tacrolimus Formulation Administered to Living-Donor Liver Transplant Recipients. <i>Experimental and Clinical Transplantation</i> , <b>2016</b> , 14, 412-8	0.8	2

37	Solid Organ Transplant. <b>2017</b> ,		
36	Interakce mezi mykofenolŕ mofetilem a takrolimem u pacientŕpo transplantaci ledviny. <i>Klinicka Farmakologie A Farmacie</i> , <b>2017</b> , 31, 3-6	0.1	
35	Influence of different formulations of tacrolimus on dosage regimen and drug exposure within the first year after kidney transplantation. <i>Hospital Pharmacology</i> , <b>2019</b> , 6, 774-784	0.2	0
34	Bioequivalence of two tacrolimus 1-mg formulations under fasting conditions in healthy subjects: A randomized, two-period crossover trial?. <i>International Journal of Clinical Pharmacology and Therapeutics</i> , <b>2020</b> , 58, 183-193	2	0
33	Therapeutic drug monitoring of immunosuppressants. <b>2020</b> , 317-332		
32	Chapter 11: Immunology: Tacrolimus/CYP3A5 Case. <b>2020</b> ,		
31	Monitoring Tacrolimus Trough Concentrations During the First Year After Kidney Transplantation: A National Retrospective Cohort Study. <i>Frontiers in Pharmacology</i> , <b>2020</b> , 11, 566638	5.6	1
30	[Summary of the recommendations of the International Association of Therapeutic Drug Monitoring and Clinical Toxicology (IATDMCT) on the therapeutic drug monitoring of tacrolimus]. <i>Therapie</i> , <b>2020</b> , 75, 681-685	3.8	1
29	Relationships of related genetic polymorphisms and individualized medication of tacrolimus in patients with renal transplantation. <i>International Journal of Clinical and Experimental Medicine</i> , <b>2015</b> , 8, 19006-13		2
28	Variations in Practice to Therapeutic Monitoring of Tacrolimus following Primary Adult Liver Transplantation. <i>International Journal of Organ Transplantation Medicine</i> , <b>2016</b> , 7, 1-8	0.7	7
27	Machine learning-based method for tacrolimus dose predictions in Chinese kidney transplant perioperative patients. <i>Journal of Clinical Pharmacy and Therapeutics</i> , <b>2021</b> ,	2.2	3
26	Comparing weight-based dosing of tacrolimus XR in obese and non-obese renal transplant recipients. <i>Clinical Transplantation</i> , <b>2021</b> , e14529	3.8	
25	An Unusual Presentation of Posterior Reversible Encephalopathy Syndrome Following Liver Transplantation.. <i>Transplantation Direct</i> , <b>2022</b> , 8, e1269	2.3	
24	Race and sex associations with tacrolimus pharmacokinetics in stable kidney transplant recipients.. <i>Pharmacotherapy</i> , <b>2022</b> ,	5.8	1
23	Predicting model-informed precision dosing: a test-case in tacrolimus dose adaptation for kidney transplant recipients.. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , <b>2022</b> ,	4.5	1
22	Lower versus Higher Starting Tacrolimus Dosing in Kidney Transplant Recipients.. <i>Clinical Transplantation</i> , <b>2022</b> , e14606	3.8	
21	Effect of Wuzhi capsules on cyclosporine A concentration in children with aplastic anemia immunotherapy: a single-center observational study.. <i>Expert Review of Clinical Pharmacology</i> , <b>2022</b> ,	3.8	
20	PharmVar GeneFocus: CYP3A5.. <i>Clinical Pharmacology and Therapeutics</i> , <b>2022</b> ,	6.1	0

19	Efficacy and outcomes of CYP3A5 genotype-based tacrolimus dosing compared to conventional body weight-based dosing in living donor kidney transplant recipients. <i>Indian Journal of Nephrology</i> , <b>2022</b> ,	0.8	
18	The pharmacokinetics of tacrolimus in peripheral blood mononuclear cells and limited sampling strategy for estimation of exposure in renal transplant recipients.. <i>European Journal of Clinical Pharmacology</i> , <b>2022</b> ,	2.8	
17	Renal Cyp3a5-Expressing Genotype Decreases Tacrolimus-to-Dose Ratio in Small Cohort of Renal Transplant Recipients-Preliminary Report.. <i>Transplantation Proceedings</i> , <b>2022</b> ,	1.1	
16	Topical calcineurin inhibitors. <b>2013</b> , 535-542.e4		1
15	Prolonged-Release Once-Daily Formulation of Tacrolimus Versus Standard-of-Care Tacrolimus in de novo Kidney Transplant Patients Across Europe. <i>Transplant International</i> , 35,	3	0
14	Therapeutic Drug Monitoring of Tacrolimus-Personalized Therapy in Heart Transplantation: New Strategies and Preliminary Results in Endomyocardial Biopsies. <i>Pharmaceutics</i> , <b>2022</b> , 14, 1247	6.4	
13	Immunosuppression in liver transplanted patients with short bowel syndrome.. <i>Journal of Liver Transplantation</i> , <b>2022</b> , 100115		
12	The effect of the very low dosage diltiazem on tacrolimus exposure very early after kidney transplantation: a randomized controlled trial. <b>2022</b> , 12,		0
11	CYP3A4/5 genotypes and age codetermine tacrolimus concentration and dosage in pediatric heart transplant recipients. <b>2022</b> , 111, 109164		
10	Compare the performance of multiple machine learning models in predicting tacrolimus concentration for infant patients with living donor liver transplantation.		0
9	Chapter 11: Immunology: Tacrolimus/CYP3A5 Case. <b>2022</b> ,		0
8	Frequencies and Association of CYP3A5 Polymorphism With Tacrolimus Concentration Among Renal Transplant Recipients in Vietnam. <b>2022</b> ,		0
7	Population pharmacokinetics of sublingually administered tacrolimus in infants and young children with liver transplantation.		0
6	Biosensing Tacrolimus in Human Whole Blood by Using a Drug Receptor Fused to the Emerald Green Fluorescent Protein.		0
5	Therapeutic Drug Monitoring of Tacrolimus Based on Volumetric Absorptive Microsampling Technique (VAMS) in Renal Transplant Pediatric Recipients—C-MS/MS Method Development, Hematocrit Effect Evaluation, and Clinical Application. <b>2023</b> , 15, 299		0
4	Therapeutic challenges of tacrolimus dose requirement and trough level in an indian pediatric renal transplant recipient with extensive metabolizer (Cytochrome P450 3A5*1). <b>2023</b> , 17, 124		0
3	Envarsus XR □ pharmacokinetics in adolescents post-kidney transplantation □A pilot study. <b>2023</b> , 27,		0
2	A Multi-Centre Non-Interventional Study to Assess the Tolerability and Effectiveness of Extended-Release Tacrolimus (LCPT) in De Novo Liver Transplant Patients. <b>2023</b> , 12, 2537		0

- 1 Does the Tacrolimus Trough Level Adequately Predict Drug Exposure in Patients Requiring a High Tacrolimus Dose?. **2023**, 9, e1439

o